OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease, announced today that a key
milestone has been accomplished in the proposed business
combination with Curetis, N.V. (Euronext: CURE, “Curetis”), a
developer of next-level molecular diagnostic solutions. On January
27, 2020, OpGen filed and furnished to its stockholders a proxy
statement/prospectus and a notice of special meeting of OpGen
stockholders, to be held on March 10, 2020 at 10:00am ET at the
offices of Ballard Spahr LLP, 1909 K Street, NW, 12 th Floor,
Washington DC. At the special meeting, OpGen is seeking
shareholder approval of the business combination of OpGen and
Curetis. Curetis will host its shareholder meeting on the same day
at 1:00pm CET with the same objective. The Curetis extraordinary
general meeting will take place at Steigenberger Hotel,
Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam,
the Netherlands. Successful votes of the shareholders of the
respective companies are the last remaining major steps towards
closing of the transaction.
“We are confident that the combination of OpGen
and Curetis will help maximize value for our stockholders and will
result in an organization with a robust pipeline of proprietary
molecular diagnostic and bioinformatics products, significant
management experience, and unique assets for developing and
commercializing novel data-driven solutions in infectious disease
diagnostics,” said Evan Jones, Chairman and CEO of OpGen.
“I expect the combination with OpGen to
accelerate the commercial development and revenue growth for both
companies and that it will ultimately bring tremendous value to the
combined company and its current and future shareholders,” said
Oliver Schacht, CEO of Curetis. “We look forward to moving the
Company ahead into this next exciting chapter.”
H.C. Wainwright & Co., LLC and Crosstree
Capital LLC acted as financial advisors to Curetis and OpGen,
respectively. Linklaters LLP and Ballard Spahr LLP acted as legal
advisors to Curetis and OpGen, respectively.
About OpGen
OpGen, Inc. is a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease. We are developing molecular
information products and services for global healthcare settings,
helping to guide clinicians with more rapid and actionable
information about life threatening infections, improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs.
Our molecular diagnostics and informatics
products, product candidates and services combine our Acuitas
molecular diagnostics and Acuitas Lighthouse informatics platform
for use with our proprietary, curated MDRO knowledgebase. We are
working to deliver our products and services, some in development,
to a global network of customers and partners. The Acuitas AMR Gene
Panel (RUO) is intended for Research Use Only and is not for use in
diagnostic procedures. The Acuitas Lighthouse Software is not
distributed commercially for antibiotic resistance prediction and
is not for use in diagnostic procedures. For more information,
please visit www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are
registered trademarks of OpGen, Inc.
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly-owned subsidiary Ares Genetics
GmbH offers next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
what the Company believes to be the most comprehensive database
worldwide on the genetics of antimicrobial resistances, ARESdb,
with advanced bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Forward-Looking Statements – OpGen,
Inc
This press release includes statements relating
to the proposed business combination between OpGen and Curetis.
These statements and other statements regarding OpGen’s and the
combined company’s future plans constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond OpGen’s control, and
which may cause results to differ materially from expectations.
Factors that could cause results to differ materially from those
described include, but are not limited to, our ability to
successfully and timely seek approval of, and obtain approval of
our stockholders for the transaction, satisfy the closing
conditions under the implementation agreement between OpGen and
Curetis, successfully combine the businesses of OpGen and Curetis,
comply with the complexities of a global business, achieve the
synergies we expect, successfully implement the combined company’s
strategic and business goals and objectives, and advance our
current and planned 510(k) clearance submissions with the FDA, and
risks and uncertainties associated with market conditions, advance
our current. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the SEC. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen: Michael Farmer Vice
President, Marketing (240) 813-1284 mfarmer@opgen.com
InvestorRelations@opgen.com
OpGen Press Contact: Matthew
Bretzius FischTank Marketing and PR matt@fischtankpr.com
OpGen Investor Contact: Joe
Green Edison Group jgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024